For a full list of publications click here.
Peer Reviewed Publications
Leukemic transformation by theMLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA.
Blood. 2013 Mar 28; 121(13):2533-41.
DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-
specific and other intestinalepithelial
functions.
Ho L-L, Sinha A, Verzi M, Bernt KM, Armstrong S,
Shivdasani RA.
Mol Cell Biol. 2013 May; 33(9): 1735-45.
Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ.
Nature. 2012 Mar 4;483(7391):598-602. doi: 10.1038/nature10953.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA.
Cancer Cell. 2011 Jul 12;20(1):66-78.
Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM.
Cancer Cell. 2011 Jul 12;20(1):53-65.
Reviews
Bernt KM, Armstrong SA.
Epigenomics. 2011 Dec; 3(6): 667-70.
Bernt KM, Armstrong SA.
Hematology Am Soc Hematol Educ Program. 2011; 354-60.
Bernt KM, Armstrong SA.
Semin Hematol. 2009 Jan; 46(1):33-8.